Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PACERONE vs MEMBRANEBLUE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Class III antiarrhythmic agent; prolongs action potential duration and refractory period by blocking potassium channels, and also exhibits class I, II, and IV effects.
Methylene blue (Membraneblue) is a selective inhibitor of guanylyl cyclase, thereby reducing cyclic guanosine monophosphate (c GMP) levels. It also acts as an electron carrier in the reduction of methemoglobin to hemoglobin.
Life-threatening recurrent ventricular arrhythmias (e.g., ventricular fibrillation, hemodynamically unstable ventricular tachycardia),Atrial fibrillation and atrial flutter (off-label may include maintenance of sinus rhythm)
Treatment of acquired methemoglobinemia,Diagnostic staining (e.g., parathyroid glands, lymphatic mapping),Off-label: Refractory vasoplegic shock, prevention of ifosfamide neurotoxicity
Loading dose: 800-1600 mg/day PO in divided doses for 1-3 weeks, then 600-800 mg/day PO for 1 month; maintenance: 200-400 mg/day PO once daily. IV: 150 mg over 10 min, then 1 mg/min for 6 hours, then 0.5 mg/min.
2 mg/kg intravenously once, administered over 30 minutes; may repeat once if clinically indicated after 30 minutes.
Biphasic: initial 3-10 days; terminal elimination half-life 40-58 days (mean ~53 days) due to extensive tissue distribution and slow release from fat. Clinical context: steady-state achieved in 2-4 months without loading dose.
Terminal elimination half-life 2.5-3.5 hours in adults; prolonged in hepatic or renal impairment (up to 6-8 hours).
Primarily hepatic via CYP3A4 and CYP2C8; active metabolite desethylamiodarone; substrate of P-glycoprotein.
Reduced by NADPH-dependent methemoglobin reductase to leukomethylene blue; excreted in urine and bile.
Primarily hepatic metabolism (CYP3A4, CYP2C8) to desethylamiodarone (active). Renal elimination of drug and metabolites: <1% of unchanged drug; ~40% of dose as metabolites. Fecal elimination: ~70% of dose as metabolites, with some parent drug.
Renal: approximately 60-70% unchanged; biliary/fecal: 20-30% as conjugated metabolites; minor pulmonary excretion.
96% bound, primarily to albumin and beta-lipoproteins.
Approximately 85-90% bound to albumin and alpha-1-acid glycoprotein.
66 L/kg (range 10-200 L/kg) indicating extensive tissue distribution, especially in adipose tissue, liver, and lungs.
0.35-0.45 L/kg, indicating primarily extracellular distribution.
Oral: 30-80% (mean ~50%), increased by food; erratic absorption due to high lipophilicity. IV: 100%.
Intravenous: 100% (only route); oral bioavailability negligible (<1%) due to extensive first-pass metabolism.
No specific GFR-based dose adjustment required; caution in severe renal impairment due to possible accumulation of active metabolite desethylamiodarone. Monitor serum levels and QT interval.
No specific dose adjustment recommended; use caution in severe renal impairment (e GFR <30 m L/min/1.73 m²) due to limited data.
Contraindicated in severe hepatic disease (Child-Pugh class C). In moderate impairment (Child-Pugh class B), reduce maintenance dose by 50% and monitor liver function. Mild impairment (Child-Pugh A): no adjustment, but monitor.
No specific dose adjustment recommended; use with caution in severe hepatic impairment (Child-Pugh Class C) due to potential for altered metabolism.
Loading: 10-20 mg/kg/day PO in divided doses for 7-10 days; maintenance: 5-10 mg/kg/day PO once daily. IV loading: 5 mg/kg over 30 min, then 5-15 mg/kg/day continuous infusion.
2 mg/kg intravenously once, not to exceed 100 mg total dose; repeat dosing not typically recommended.
Lower maintenance doses (100-200 mg/day PO) due to increased risk of bradycardia, QT prolongation, and thyroid dysfunction. Monitor renal function and electrolytes closely.
No specific dose adjustment required; monitor for renal function and fluid overload due to age-related physiological changes.
Only for patients with life-threatening arrhythmias due to risk of pulmonary toxicity, hepatotoxicity, and proarrhythmia; requires baseline and periodic monitoring of pulmonary function, liver enzymes, thyroid function, and ECG.
Serotonin syndrome with concurrent serotonergic drugs (especially SSRIs, SNRIs, MAOIs); discontinue serotonergic agents prior to use; do not use in patients taking serotonergic drugs.
Pulmonary toxicity (interstitial pneumonitis, pulmonary fibrosis), hepatotoxicity (elevated liver enzymes, hepatic failure), proarrhythmia (worsening arrhythmias, torsades de pointes), thyroid dysfunction (hypo- or hyperthyroidism), optic neuropathy/neuritis, skin discoloration, photosensitivity, bradycardia, and drug interactions (CYP450 and P-gp mediated).
Risk of serotonin syndrome when used with serotonergic agents; may cause severe hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency; may cause interferences with pulse oximetry readings; monitor methemoglobin levels; may cause fetal harm.
Cardiogenic shock, severe sinus node dysfunction (without pacemaker), second- or third-degree AV block (without pacemaker), marked bradycardia, and hypersensitivity to amiodarone or iodine.
Known hypersensitivity to methylene blue; concurrent use with serotonergic drugs (SSRIs, SNRIs, MAOIs); severe G6PD deficiency.
Avoid grapefruit juice as it inhibits CYP3A4 and can increase amiodarone levels. St. John's wort may decrease amiodarone efficacy by inducing metabolism. Take with food to reduce gastrointestinal irritation.
No known food interactions. Avoid alcohol consumption for 24 hours post-administration due to potential increased sedative effects.
Pacerone (amiodarone) is FDA Pregnancy Category D. First trimester: risk of congenital anomalies including hypothyroidism, goiter, and neurodevelopmental delays due to iodine content. Second and third trimesters: continued risk of fetal hypothyroidism and bradycardia; neonatal monitoring for thyroid function and ECG is recommended.
Current evidence indicates no increased risk of major congenital malformations with prenatal exposure. No known fetal risks during any trimester. However, human data are limited.
Amiodarone is excreted into breast milk with an M/P ratio of approximately 0.1-1.0. Due to significant accumulation in infant tissues and long half-life, breastfeeding is contraindicated because of potential for neonatal hypothyroidism and bradycardia.
Breastfeeding safety not established. M/P ratio unknown. Use caution during lactation due to potential for excretion.
Pregnancy increases volume of distribution and clearance of amiodarone, potentially requiring dose adjustments to maintain therapeutic levels. However, due to risks, use is limited to severe arrhythmias and doses should be minimized. Monitoring of serum levels is recommended to guide dosing.
No dose adjustment required based on pharmacokinetic changes during pregnancy.
Amiodarone has an extremely long half-life (up to 107 days) causing delayed onset and prolonged effects. Monitor for thyroid dysfunction, pulmonary fibrosis, liver toxicity, and corneal deposits. Avoid coadministration with drugs prolonging QT interval. Use lowest effective dose due to cumulative toxicity.
MEMBRANEBLUE (methylene blue) 1% solution is used intravenously for methemoglobinemia and as an optical imaging agent. Monitor for serotonergic toxicity if combined with SSRIs/SNRIs due to MAO inhibition. Do not exceed 7 mg/kg total dose to avoid severe adverse effects. Use with caution in G6PD deficiency due to risk of hemolytic anemia.
Take exactly as prescribed; do not skip doses or stop without consulting your doctor.,Report any new or worsening shortness of breath, cough, chest pain, or palpitations.,Inform your doctor if you experience vision changes, thyroid symptoms (weight change, heat/cold intolerance), or skin discoloration.,Avoid grapefruit juice and St. John's wort as they may affect drug levels.,Use sun protection; amiodarone increases sun sensitivity.,Do not breastfeed while taking this medication.,Keep all follow-up appointments for blood tests, eye exams, and lung function tests.,This medication can cause birth defects; use effective contraception.
This medication may cause your urine, stool, or skin to turn blue-green, which is harmless and temporary.,Report any severe headache, chest pain, or difficulty breathing immediately.,Avoid taking medications for depression, anxiety, or migraine (SSRIs, SNRIs, MAOIs) within 24 hours of receiving MEMBRANEBLUE unless directed by your doctor.,If you have a history of glucose-6-phosphate dehydrogenase (G6PD) deficiency, inform your healthcare provider before treatment.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PACERONE vs MEMBRANEBLUE, answered by our medical review team.
PACERONE is a Antiarrhythmic Agent that works by Class III antiarrhythmic agent; prolongs action potential duration and refractory period by blocking potassium channels, and also exhibits class I, II, and IV effects.. MEMBRANEBLUE is a Ophthalmic Dye that works by Methylene blue (Membraneblue) is a selective inhibitor of guanylyl cyclase, thereby reducing cyclic guanosine monophosphate (c GMP) levels. It also acts as an electron carrier in the reduction of methemoglobin to hemoglobin.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PACERONE and MEMBRANEBLUE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PACERONE is: Loading dose: 800-1600 mg/day PO in divided doses for 1-3 weeks, then 600-800 mg/day PO for 1 month; maintenance: 200-400 mg/day PO once daily. IV: 150 mg over 10 min, then 1 mg/min for 6 hours, then 0.5 mg/min.. The standard adult dose of MEMBRANEBLUE is: 2 mg/kg intravenously once, administered over 30 minutes; may repeat once if clinically indicated after 30 minutes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PACERONE and MEMBRANEBLUE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PACERONE is classified as Category C. Pacerone (amiodarone) is FDA Pregnancy Category D. First trimester: risk of congenital anomalies including hypothyroidism, goiter, and neurodevelopmental delays due to iodine conte. MEMBRANEBLUE is classified as Category C. Current evidence indicates no increased risk of major congenital malformations with prenatal exposure. No known fetal risks during any trimester. However, human data are limited.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.